Odds & Ends & Interpretations Posted: September 28, 2006 A couple of past subjects worthy of follow-up comment: The Vioxx Trial Scorecard: Merck won a recent case in New Orleans, but has it made any progress? Interpreting Rozerem DTC: A couple of suspicious characters posted comments that reveal the real message behind the Rozerem DTC ads. Takeda better tread carefully! For more on these topics, please read today's post to Pharma Marketing Blog. For more posts in related topic areas, see: Drug Companies Pain Drugs (Vioxx, etc.) Sleep Aid Drugs DTC Advertising If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe. Enter your Email Address | Return to Pharma Marketing Blog Topics |

Special Supplement eDetailing This Special Supplement to Pharma Marketing News brings together in one convenient document several topics and case studies on eDetailing and ePromotion to physicians. The resultant collective wisdom of many experts both inside pharmaceutical companies and outside provide a frank assessment of the role and impact of eDetailing on physician marketing as well as the challenges that lie ahead. INCLUDES THESE BONUS REPRINTS: Beyond the eDetail: Evolving to Educate eDetailing: Yesterday, Today and Tomorrow TABLE OF CONTENTS REDUCED PRICE! ONLY $19.95 Order and pay for this Special Supplement now using your credit card. PDF file delivered to you by email (usually within minutes of placing your order): If you wish to be pay by check or credit card off-line, please use: Printable Order Form